Hypoxia in head and neck tumors: Characteristics and development during therapy

Frontiers in Oncology

Volumn 3 AUG, Issue , 2013, Pages

  Bittner, Martin Immanuel ^a   Grosu, Anca Ligia ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Biological imaging; Head and neck tumors; PET; Primary chemoradiotherapy; Tumor hypoxia

Indexed keywords

CANCER CONTROL; CHEMORADIOTHERAPY; HEAD AND NECK CANCER; HUMAN; HYPOXIA; META ANALYSIS (TOPIC); NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE; REPRODUCIBILITY; SHORT SURVEY;

EID: 84891057060     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00223     Document Type: Short Survey

References (53)

1. Begg AC. Predicting recurrence after radiotherapy in head and neck cancer. Semin Radiat Oncol (2012) 22(2):108-18. doi:10.1016/j.semradonc.2011.12.002
2. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radat Oncol Biol Phys (1997) 38:285-9. doi:10.1016/S0360-3016(97)00101-6
3. Nordsmark M, Overgaard J. A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiother Oncol (2000) 57:39-43. doi:10.1016/S0167-8140(00)00223-1
4. Eschmann SM, Paulsen F, Reimold M, Dittmann H, Welz S, Reischl G, et al. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med (2005) 46(2):253-60.
5. Rischin D, Hicks RJ, Fisher R, Binns D, Corry J, Porceddu S, et al. Trans-Tasman Radiation Oncology Group Study 98.02. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol (2006) 24(13):2098-104.
6. Rajendran JG, Schwartz DL, O'Sullivan J, Peterson LM, Ng P, Scharnhorst J, et al. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res (2006) 12(18):5435-41. doi:10.1158/1078-0432.CCR-05-1773
7. Kikuchi M, Yamane T, Shinohara S, Fujiwara K, Hori SY, Tona Y, et al. 18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma. Ann Nucl Med (2011) 25(9):625-33. doi:10.1007/s12149-011-0508-9
8. Horsman MR, Mortensen LS, Petersen JB, Busk M, Overgaard J. Imaging hypoxia to improve radiotherapy outcome. Nat Rev Clin Oncol (2012) 9(12):674-87. doi:10.1038/nrclinonc.2012.171
9. Srinivasan A, Mohan S, Mukherji SK. Biologic imaging of head and neck cancer: the present and the future. AJNR Am J Neuroradiol (2012) 33(4):586-94. doi:10.3174/ajnr.A2535
10. Gagel B, Reinartz P, Dimartino E, Zimny M, Pinkawa M, Maneschi P, et al. pO(2) Polarography versus positron emission tomography ([(18)F] fluoromisonidazole, [(18)F]-2-fluoro-2'-deoxyglucose). An appraisal of radiotherapeutically relevant hypoxia. Strahlenther Onkol (2004) 180(10):616-22. doi:10.1007/s00066-004-1229-y
11. Zimny M, Gagel B, DiMartino E, Hamacher K, Coenen HH, Westhofen M, et al. FDG-a marker of tumour hypoxia? A comparison with [18F]fluoromisonidazole and pO2-polarography in metastatic head and neck cancer. Eur J Nucl Med Mol Imaging (2006) 33(12):1426-31. doi:10.1007/s00259-006-0175-6
12. Mortensen LS, Buus S, Nordsmark M, Bentzen L, Munk OL, Keiding S, et al. Identifying hypoxia in human tumors: a correlation study between 18F-FMISO PET and the Eppendorf oxygen-sensitive electrode. Acta Oncol (2010) 49(7):934-40. doi:10.3109/0284186X.2010.516274
13. Gagel B, Piroth M, Pinkawa M, Reinartz P, Zimny M, Kaiser HJ, et al. pO polarography, contrast enhanced color duplex sonography (CDS), [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography: validated methods for the evaluation of therapy-relevant tumor oxygenation or only bricks in the puzzle of tumor hypoxia? BMC Cancer (2007) 28(7):113. doi:10.1186/1471-2407-7-113
14. Souvatzoglou M, Grosu AL, Röper B, Krause BJ, Beck R, Reischl G, et al. Tumour hypoxia imaging with [18F]FAZA PET in head and neck cancer patients: a pilot study. Eur J Nucl Med Mol Imaging (2007) 34(10):1566-75. doi:10.1007/s00259-007-0424-3
15. Postema EJ, McEwan AJ, Riauka TA, Kumar P, Richmond DA, Abrams DN, et al. Initial results of hypoxia imaging using 1-alpha-D:-(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole (18F-FAZA). Eur J Nucl Med Mol Imaging (2009) 36(10):1565-73. doi:10.1007/s00259-009-1154-5
16. Minagawa Y, Shizukuishi K, Koike I, Horiuchi C, Watanuki K, Hata M, et al. Assessment of tumor hypoxia by 62Cu-ATSM PET/CT as a predictor of response in head and neck cancer: a pilot study. Ann Nucl Med (2011) 25(5):339-45. doi:10.1007/s12149-011-0471-5
17. Komar G, Seppänen M, Eskola O, Lindholm P, Grönroos TJ, Forsback S, et al. 18F-EF5: a new PET tracer for imaging hypoxia in head and neck cancer. J Nucl Med (2008) 49(12):1944-51. doi:10.2967/jnumed.108.053785
18. Chen L, Zhang Z, Kolb HC, Walsh JC, Zhang J, Guan Y. 18F-HX4 hypoxia imaging with PET/CT in head and neck cancer: a comparison with 18F-FMISO. Nucl Med Commun (2012) 33(10):1096-102. doi:10.1097/MNM.0b013e3283571016
19. Thorwarth D, Eschmann SM, Scheiderbauer J, Paulsen F, Alber M. Kinetic analysis of dynamic 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer. BMC Cancer (2005) 5:152. doi:10.1186/1471-2407-5-152
20. Wang W, Georgi JC, Nehmeh SA, Narayanan M, Paulus T, Bal M, et al. Evaluation of a compartmental model for estimating tumor hypoxia via FMISO dynamic PET imaging. Phys Med Biol (2009) 54(10):3083-99. doi:10.1088/0031-9155/54/10/008
21. Shi K, Souvatzoglou M, Astner ST, Vaupel P, Nüsslin F, Wilkens JJ, et al. Quantitative assessment of hypoxia kinetic models by a cross-study of dynamic 18F-FAZA and 15O-H2O in patients with head and neck tumors. J Nucl Med (2010) 51(9):1386-94. doi:10.2967/jnumed.109.074336
22. Newbold K, Castellano I, Charles-Edwards E, Mears D, Sohaib A, Leach M, et al. An exploratory study into the role of dynamic contrast-enhanced magnetic resonance imaging or perfusion computed tomography for detection of intratumoral hypoxia in head-and-neck cancer. Int J Radiat Oncol Biol Phys (2009) 74(1):29-37. doi:10.1016/j.ijrobp.2008.07.039
23. Truong MT, Saito N, Ozonoff A, Wang J, Lee R, Qureshi MM, et al. Prediction of locoregional control in head and neck squamous cell carcinoma with serial CT perfusion during radiotherapy. AJNR Am J Neuroradiol (2011) 32(7):1195-201. doi:10.3174/ajnr.A2501
24. Lee N, Nehmeh S, Schöder H, Fury M, Chan K, Ling CC, et al. Prospective trial incorporating pre-/mid-treatment [18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys (2009) 75(1):101-8. doi:10.1016/j.ijrobp.2008.10.049
25. Zips D, Zöphel K, Abolmaali N, Perrin R, Abramyuk A, Haase R, et al. Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer. Radiother Oncol (2012) 105(1):21-8. doi:10.1016/j.radonc.2012.08.019
26. Dirix P, Vandecaveye V, De Keyzer F, Stroobants S, Hermans R, Nuyts S. Dose painting in radiotherapy for head and neck squamous cell carcinoma: value of repeated functional imaging with (18)F-FDG PET, (18)F-fluoromisonidazole PET, diffusion-weighted MRI, and dynamic contrast-enhanced MRI. J Nucl Med (2009) 50(7):1020-7. doi:10.2967/jnumed.109.062638
27. Mortensen LS, Johansen J, Kallehauge J, Primdahl H, Busk M, Lassen P, et al. FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial. Radiother Oncol (2012) 105(1):14-20. doi:10.1016/j.radonc.2012.09.015
28. Tachibana I, Nishimura Y, Shibata T, Kanamori S, Nakamatsu K, Koike R, et al. A prospective clinical trial of tumor hypoxia imaging with 18F-fluoromisonidazole positron emission tomography and computed tomography (F-MISO PET/CT) before and during radiation therapy. J Radiat Res (2013). doi:10.1093/jrr/rrt033. [Epub ahead of print].
29. Bittner MI, Wiedenmann N, Bucher S, Hentschel M, Mix M, Weber WA, et al. Exploratory geographical analysis of hypoxic subvolumes using 18F-MISO-PET imaging in patients with head and neck cancer in the course of primary chemoradiotherapy. Radiother Oncol (2013). doi:10.1016/j.radonc.2013.06.012. [Epub ahead of print].
30. Lin Z, Mechalakos J, Nehmeh S, Schoder H, Lee N, Humm J, et al. The influence of changes in tumor hypoxia on dose-painting treatment plans based on 18F-FMISO positron emission tomography. Int J Radiat Oncol Biol Phys (2008) 70(4):1219-28. doi:10.1016/j.ijrobp.2007.09.050
31. Nehmeh SA, Lee NY, Schröder H, Squire O, Zanzonico PB, Erdi YE, et al. Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys (2008) 70(1):235-42. doi:10.1016/j.ijrobp.2007.08.036
32. Okamoto S, Shiga T, Yasuda K, Ito YM, Magota K, Kasai K, et al. High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer. J Nucl Med (2013) 54(2):201-7. doi:10.2967/jnumed.112.109330
33. Mönnich D, Troost EG, Kaanders JH, Oyen WJ, Alber M, Thorwarth D. Modelling and simulation of the influence of acute and chronic hypoxia on [18F]fluoromisonidazole PET imaging. Phys Med Biol (2012) 57(6):1675-84. doi:10.1088/0031-9155/57/6/1675
34. Toma-Dasu I, Uhrdin J, Antonovic L, Dasu A, Nuyts S, Dirix P, et al. Dose prescription and treatment planning based on FMISO-PET hypoxia. Acta Oncol (2012) 51(2):222-30. doi:10.3109/0284186X.2011.599815
35. Stadler P, Feldmann HJ, Creighton C, Kau R, Molls M. Changes in tumor oxygenation during combined treatment with split-course radiotherapy and chemotherapy in patients with head and neck cancer. Radiother Oncol (1998) 48(2):157-64. doi:10.1016/S0167-8140(98)00032-2
36. Thorwarth D, Eschmann SM, Paulsen F, Alber M. A model of reoxygenation dynamics of head-and-neck tumors based on serial 18F-fluoromisonidazole positron emission tomography investigations. Int J Radiat Oncol Biol Phys (2007) 68(2):515-21. doi:10.1016/j.ijrobp.2006.12.037
37. Eschmann SM, Paulsen F, Bedeshem C, Machulla HJ, Hehr T, Bamberg M, et al. Hypoxia-imaging with (18)F-Misonidazole and PET: changes of kinetics during radiotherapy of head-and-neck cancer. Radiother Oncol (2007) 83(3):406-10. doi:10.1016/j.radonc.2007.05.014
38. Hicks RJ, Rischin D, Fisher R, Binns D, Scott AM, Peters LJ. Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent. Eur J Nucl Med Mol Imaging (2005) 32(12):1384-91. doi:10.1007/s00259-005-1880-2
39. Wang K, Yorke E, Nehmeh SA, Humm JL, Ling CC. Modeling acute and chronic hypoxia using serial images of 18F-FMISO PET. Med Phys (2009) 36(10):4400-8. doi:10.1118/1.3213092
40. Sun Q, Li X, Lu X, Di B. Cancer stem cells may be mostly maintained by fluctuating hypoxia. Med Hypotheses (2011) 76(4):471-3. doi:10.1016/j.mehy.2010.11.023
41. Vercellino L, Groheux D, Thoury A, Delord M, Schlageter MH, Delpech Y, et al. Hypoxia imaging of uterine cervix carcinoma with (18)F-FETNIM PET/CT. Clin Nucl Med (2012) 37(11):1065-8. doi:10.1097/RLU.0b013e3182638e7e
42. Segard T, Robins PD, Yusoff IF, Ee H, Morandeau L, Campbell EM, et al. Detection of hypoxia with 18F-fluoromisonidazole (18F-FMISO) PET/CT in suspected or proven pancreatic cancer. Clin Nucl Med (2013) 38(1):1-6. doi:10.1097/RLU.0b013e3182708777
43. Askoxylakis V, Dinkel J, Eichinger M, Stieltjes B, Sommer G, Strauss LG, et al. Multimodal hypoxia imaging and intensity modulated radiation therapy for unresectable non-small-cell lung cancer: the HIL trial. Radiat Oncol (2012) 14(7):157. doi:10.1186/1748-717X-7-157
44. Grosu AL, Souvatzoglou M, Röper B, Dobritz M, Wiedenmann N, Jacob V, et al. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Int J Radiat Oncol Biol Phys (2007) 69(2):541-51. doi:10.1016/j.ijrobp.2007.05.079
45. Lee NY, Mechalakos JG, Nehmeh S, Lin Z, Squire OD, Cai S, et al. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys (2008) 70(1):2-13. doi:10.1016/j.ijrobp.2007.06.039
46. Thorwarth D, Eschmann SM, Paulsen F, Alber M. Hypoxia dose painting by numbers: a planning study. Int J Radiat Oncol Biol Phys (2007) 68(1):291-300. doi:10.1016/j.ijrobp.2006.11.061
47. Thorwarth D, Alber M. Individualised radiotherapy on the basis of functional imaging with FMISO PET. Z Med Phys (2008) 18(1):43-50. doi:10.1016/j.zemedi.2007.08.003
48. Hendrickson K, Phillips M, Smith W, Peterson L, Krohn K, Rajendran J. Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance. Radiother Oncol (2012) 101(3):369-75. doi:10.1016/j.radonc.2011.07.029
49. Chang JH, Wada M, Anderson NJ, Lim Joon D, Lee ST, Gong SJ, et al. Hypoxia-targeted radiotherapy dose painting for head and neck cancer using (18)F-FMISO PET: a biological modeling study. Acta Oncol (2013). doi:10.3109/0284186X.2012.759273. [Epub ahead of print].
50. Overgaard J. Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck-a systematic review and meta-analysis. Radiother Oncol (2011) 100(1):22-32. doi:10.1016/j.radonc.2011.03.004
51. Quon H, Brizel DM. Predictive and prognostic role of functional imaging of head and neck squamous cell carcinomas. Semin Radiat Oncol (2012) 22(3):220-32. doi:10.1016/j.semradonc.2012.03.007
52. Karar J, Maity A. Modulating the tumor microenvironment to increase radiation responsiveness. Cancer Biol Ther (2009) 8(21):1994-2001. doi:10.4161/cbt.8.21.9988
53. Pore N, Gupta AK, Cerniglia GJ, Jiang Z, Bernhard EJ, Evans SM, et al. Nelfinavir down-regulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation: implications for radiotherapy. Cancer Res (2006) 66(18):9252-9. doi:10.1158/0008-5472.CAN-06-1239